However, additional research into the efficacy of MLH1 promoter methylation testing in each tumour type is needed, as are analyses of cost-effectiveness before expansion of screening guidance to include MMR deficiency testing of all Lynch-spectrum tumours is considered. The gene discussed is MLH1; the disease is neoplasm.